Bachem and GlyTech Nominated for Innovation Award at CPHI Worldwide Forum

Bachem and GlyTech have been shortlisted in the CPhI Pharma Awards for Innovation in Process Development category for their pioneering work in developing a scalable chemical synthesis of Interferon β-1a to be presented on the first evening of the 2013 CPhI Worldwide Conference at Messe Frankfurt.

The oral presentation entitled “Pioneering  breakthrough in the chemical synthesis of Interferon β-1a” will be given by Dr. José de Chastonay (Chief Marketing Officer, Bachem Holding AG) at CPhI Speaker`s Corner on Tuesday, 22 October 2013 at 10:30.

Interferon β-1a is a 166 amino acid long glycosylated protein and an approved drug substance to treat multiple sclerosis with a world market of more than $4 billion. There are currently three recombinant products on the market which are a mixture of at least 10 glycoforms.

Bachem and GlyTech`s pioneering breakthrough is to prove a successful chemical synthesis of this protein featuring just one specific glycosylation. First bioactivity studies demonstrated that the newly synthesized Interferon β-1a is as good as or better than the conventional recombinant product.